The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, Cohen AF, van Gerven JM.
van der Post JP, et al. Among authors: de visser sj, de kam ml.
Br J Clin Pharmacol. 2005 Aug;60(2):128-36. doi: 10.1111/j.1365-2125.2005.02396.x.
Br J Clin Pharmacol. 2005.
PMID: 16042665
Free PMC article.
Clinical Trial.